Keyword Suggestions

Results
 
 
Account Login
 
Username
 
 
 
Password
 
 
 
 
 

Library Navigation

 
 

Browse Conferences

 
 
 
31 Results Found, Showing 1 - 31
Sort By:
View:
Filter By:
Date/Time
Conference
Keyword
My Content
Start Date/Time:
End Date/Time:
 
Go
 
Conference
 
Keywords:
Click here to clear this filter
 
 
Go
Show only the content that I own
 
 
February 5, 2010 - Friday
 
rating
104 - EGFR Mutation Testing and How it May Influence Therapy in Patients with NSCLC 
Relevancy:
100.00% 
 
Date/Time:
February 5, 2010   11:05am - 11:35am
 
Length:
80 Slides  
 
Total Credits:
1.00 CE / 0.50 CME  
 
Speaker:
Corey J. Langer, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
October 17, 2009 - Saturday
 
rating
SA01 - Molecular Characteristics of NSCLC 
Relevancy:
35.63% 
 
Date/Time:
October 17, 2009   8:10am - 8:45am
 
Length:
24m 31s - 36 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
John Minna, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA01 - Molecular Characteristics of NSCLC 
Relevancy:
35.63% 
 
Date/Time:
October 17, 2009   8:10am - 8:45am
 
Length:
24m 31s - 36 Slides  
 
Speaker:
John Minna, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA04 - Latest Targeted Therapies for Breast Cancer 
Relevancy:
13.74% 
 
Date/Time:
October 17, 2009   9:55am - 10:30am
 
Length:
31m 03s - 45 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Ruth O'Regan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA04 - Latest Targeted Therapies for Breast Cancer 
Relevancy:
13.74% 
 
Date/Time:
October 17, 2009   9:55am - 10:30am
 
Length:
31m 03s - 45 Slides  
 
Speaker:
Ruth O'Regan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA07 - mTor Pathways as a New Target in Endometrial and Ovarian Cancers 
Relevancy:
17.65% 
 
Date/Time:
October 17, 2009   1:00pm - 1:35pm
 
Length:
19m 47s - 26 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Marcela Del Carmen, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA07 - mTor Pathways as a New Target in Endometrial and Ovarian Cancers 
Relevancy:
17.65% 
 
Date/Time:
October 17, 2009   1:00pm - 1:35pm
 
Length:
19m 47s - 26 Slides  
 
Speaker:
Marcela Del Carmen, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA08 - Using Targeted Agents (EGFR and VEGF Inhibitors) as Radiation Modifiers 
Relevancy:
49.49% 
 
Date/Time:
October 17, 2009   1:35pm - 2:10pm
 
Length:
26m 41s - 36 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
David B. Solit, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA08 - Using Targeted Agents (EGFR and VEGF Inhibitors) as Radiation Modifiers 
Relevancy:
49.49% 
 
Date/Time:
October 17, 2009   1:35pm - 2:10pm
 
Length:
26m 41s - 36 Slides  
 
Speaker:
David B. Solit, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA11 - The Future of Oncology - Drugs in the Pipeline 
Relevancy:
52.24% 
 
Date/Time:
October 17, 2009   3:35pm - 4:10pm
 
Length:
43m 03s - 31 Slides  
 
Total Credits:
0.50 CME  
 
Speaker:
Bruce A. Chabner, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
SA11 - The Future of Oncology - Drugs in the Pipeline 
Relevancy:
52.24% 
 
Date/Time:
October 17, 2009   3:35pm - 4:10pm
 
Length:
43m 03s - 31 Slides  
 
Speaker:
Bruce A. Chabner, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 24, 2009 - Thursday
 
U106 - New Targets, New Agents, New Trials for Bladder Cancer 
Relevancy:
12.67% 
 
Date/Time:
September 24, 2009   4:05pm - 4:35pm
 
Length:
28m 15s - 52 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Dean F. Bajorin, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM106 - JAK2 Mutations in MPD: A Worthy Therapeutic Target? 
Relevancy:
39.78% 
 
Date/Time:
September 24, 2009   4:05pm - 4:35pm
 
Length:
48m 47s - 46 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Olatoyosi Odenike, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
S102 - Moving Molecular Pathways to New Diagnostic Categories and New Therapeutic Strategies 
Relevancy:
41.04% 
 
Date/Time:
September 24, 2009   4:35pm - 5:05pm
 
Length:
24m 51s - 33 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
William Tap, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
S103 - Current Best Practices in the Multidisciplinary Management of GIST 
Relevancy:
32.23% 
 
Date/Time:
September 24, 2009   5:10pm - 5:40pm
 
Length:
21m 57s - 52 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Robert G. Maki, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
U108 - What is the Standard of Care for Metastatic Renal Cell Carcinoma: First-line, Second-line? 
Relevancy:
16.24% 
 
Date/Time:
September 24, 2009   5:10pm - 5:40pm
 
Length:
21m 35s - 56 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Dean F. Bajorin, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM108 - Therapy-Related Myeloid Neoplasms: The Price of Progress? 
Relevancy:
9.99% 
 
Date/Time:
September 24, 2009   5:10pm - 5:40pm
 
Length:
26m 24s - 50 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Wendy Stock, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 25, 2009 - Friday
 
B202 - New Directions in the Treatment of 'Triple Negative' Breast Cancer 
Relevancy:
12.18% 
 
Date/Time:
September 25, 2009   9:25am - 9:55am
 
Length:
31m 46s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Lee S. Schwartzberg, MD, FACP (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GY203 - Debate: All Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening 
Relevancy:
34.61% 
 
Date/Time:
September 25, 2009   1:30pm - 2:00pm
 
Length:
41m 26s - 51 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speakers:
Michael J. Birrer, MD, PhD (Speaker Disclosure)
 
Beth Y. Karlan, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
ON204 - GI Cancers: Top Ten Breakthroughs 2008-2009 - A Literature Review 
Relevancy:
23.19% 
 
Date/Time:
September 25, 2009   2:05pm - 2:35pm
 
Length:
27m 57s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Shannon B. Holloway (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
B205 - A Primer on Molecular Oncology in Breast Cancer for the Clinician 
Relevancy:
18.58% 
 
Date/Time:
September 25, 2009   2:40pm - 3:10pm
 
Length:
37m 07s - 25 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
John Park, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
September 26, 2009 - Saturday
 
HM301 - CLL Treatment: Do Pre-treatment Characteristics Guide Current Treatment Choices? 
Relevancy:
18.90% 
 
Date/Time:
September 26, 2009   8:15am - 8:45am
 
Length:
22m 28s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Neil E. Kay, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
L302 - Molecular and Genomic Determinants of Lung Carcinogenesis 
Relevancy:
41.80% 
 
Date/Time:
September 26, 2009   8:50am - 9:20am
 
Length:
29m 09s - 30 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Ignacio I. Wistuba, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GI303 - Hepatocellular Carcinoma: New Trends and Contemporary Management 
Relevancy:
10.43% 
 
Date/Time:
September 26, 2009   9:25am - 9:55am
 
Length:
35m 09s - 59 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Andrew X. Zhu, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM303 - AML Therapy in the "Molecular Genetic" Era: How Does it Impact Therapeutic Approach? 
Relevancy:
36.84% 
 
Date/Time:
September 26, 2009   9:25am - 9:55am
 
Length:
40m 03s - 41 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Richard Stone, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
L304 - Current Status of Targeted Therapies in Lung Cancer 
Relevancy:
42.22% 
 
Date/Time:
September 26, 2009   1:30pm - 2:00pm
 
Length:
38m 36s - 54 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Scott Gettinger, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
GI304 - Cytotoxic and Targeted Agents in Gastroesophageal Cancer 
Relevancy:
18.20% 
 
Date/Time:
September 26, 2009   1:30pm - 2:00pm
 
Length:
38m 40s - 62 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Manish P. Shah, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM304 - Treatment of AML in Older Adults: Where are We Going? 
Relevancy:
24.38% 
 
Date/Time:
September 26, 2009   1:30pm - 2:00pm
 
Length:
26m 50s - 48 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Mikkael A. Sekeres, MD, MS (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
rating
HM306 - Optimizing CML Therapy in 2009: Mission Accomplished? 
Relevancy:
35.48% 
 
Date/Time:
September 26, 2009   4:05pm - 4:35pm
 
Length:
36m 04s - 77 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Neil Shah, MD, PhD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
L308 - Personalized Targeted Therapy in Lung Cancer 
Relevancy:
28.35% 
 
Date/Time:
September 26, 2009   4:40pm - 5:10pm
 
Length:
55m 05s - 55 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Waun Ki Hong, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
HM307 - Treatment of APL in 2009: Cures Without Chemotherapy? 
Relevancy:
14.79% 
 
Date/Time:
September 26, 2009   4:40pm - 5:10pm
 
Length:
31m 20s - 49 Slides  
 
Total Credits:
0.50 CME/CE  
 
Speaker:
Farhad Ravandi-Kashani, MD (Speaker Disclosure)
 
Format:
     
  Synched Audio / Slides
 

 
31 Results Found, Showing 1 - 31